🇺🇸 FDA
Patent

US 7470775

Anti-CD30 stalk and anti-CD30 antibodies suitable for use in immunotoxins

granted A61KA61K2039/505A61K47/6829

Quick answer

US patent 7470775 (Anti-CD30 stalk and anti-CD30 antibodies suitable for use in immunotoxins) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Dec 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Dec 30 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
37
CPC classes
A61K, A61K2039/505, A61K47/6829, A61K47/6849, A61K51/1027